Zytiga Favourable Over Jevtana

The majority of current Zytiga prescribers that are oncologists or urologists are satisfied with Zytiga’s overall clinical performance, but in the docetaxel-treated MCRPC setting Sanofi’s Jevtana (cabazitaxel) poses considerable competition to Zytiga. However, the vast majority of surveyed oncologists and urologists consider Zytiga to be favourable over Jevtana. In various different docetaxel-treated MCRPC patient sub-populations, Zytiga has already captured greatest patient share out of any currently available therapy according to surveyed urologists and oncologists in the USA.

While uptake of Zytiga is significant in the docetaxel-treated MCRPC patient population, physicians also believe use of Zytiga prechemotherapy is appropriate in multiple other prostate cancer patient populations.